These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 20148496)

  • 1. FPIN's clinical inquiries. Combination therapy for postmenopausal osteoporosis.
    Howard E; Tagliarino-Jones H
    Am Fam Physician; 2010 Feb; 81(4):439. PubMed ID: 20148496
    [No Abstract]   [Full Text] [Related]  

  • 2. [Effects of SERMs on bone health. Combination therapy with raloxifene].
    Gorai I; Hori H
    Clin Calcium; 2010 Mar; 20(3):408-12. PubMed ID: 20190371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Long term effects of raloxifen on the bones].
    Eiken PA
    Ugeskr Laeger; 2008 Jan; 170(4):224-6. PubMed ID: 18282451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of osteoporosis: combination therapies.
    Simon JA; Mack CJ
    Int J Fertil Womens Med; 2003; 48(3):127-31; discussion 137-8. PubMed ID: 12839144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Combination therapy for osteoporosis].
    Kishimoto H
    Nihon Rinsho; 2009 May; 67(5):975-9. PubMed ID: 19432119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Parathyroid and bone. Role of parathyroid hormone in the treatment of osteoporosis].
    Nakamura T
    Clin Calcium; 2007 Dec; 17(12):1823-9. PubMed ID: 18057656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evidence-based assessment of therapeutic agents of osteoporosis. Bisphosphonates, SERM and basic therapy in front].
    MMW Fortschr Med; 2003 Jul; 145(27-28):63. PubMed ID: 14587198
    [No Abstract]   [Full Text] [Related]  

  • 8. [Combination therapy for osteoporosis].
    Hagino H
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():316-20. PubMed ID: 18161124
    [No Abstract]   [Full Text] [Related]  

  • 9. [Parathyroid and bone. Evidence and perspective of parathyroid therapy for patients with osteoporosis].
    Wada S; Fukawa T; Kamiya S
    Clin Calcium; 2007 Dec; 17(12):1888-94. PubMed ID: 18057665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evidence for the selective estrogen receptor modulator raloxifene: its evolving role in the treatment of osteoporosis].
    Ohta H
    Clin Calcium; 2008 Oct; 18(10):1442-50. PubMed ID: 18830041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lasofoxifene: new drug. Osteoporosis: no better than raloxifene.
    Prescrire Int; 2009 Dec; 18(104):247. PubMed ID: 20020572
    [No Abstract]   [Full Text] [Related]  

  • 12. [Postmenopausal osteoporosis. Bisphosphonates are not all equal].
    MMW Fortschr Med; 2009 Mar; 151(11):46-7. PubMed ID: 19469206
    [No Abstract]   [Full Text] [Related]  

  • 13. [Therapy of osteoporosis using the ADFR schedule (especially with parathyroid hormone and etidronate)].
    Ziegler R
    Internist (Berl); 1991 Feb; 32(2):76-9. PubMed ID: 1903362
    [No Abstract]   [Full Text] [Related]  

  • 14. [Atrial fibrillation during bisphosphonate therapy. side effects or coincidental finding?].
    Ringe JD
    MMW Fortschr Med; 2009 Mar; 151(10):7. PubMed ID: 19472655
    [No Abstract]   [Full Text] [Related]  

  • 15. Combination therapies for osteoporosis.
    Jamal SA
    J Am Pharm Assoc (2003); 2004; 44(2):119; author reply 119. PubMed ID: 15098843
    [No Abstract]   [Full Text] [Related]  

  • 16. [Diphosphonate therapy and osteonecrosis of the jaw].
    Løkken P; Skoglund LA; Skjelbred P
    Tidsskr Nor Laegeforen; 2007 Aug; 127(15):1945-7. PubMed ID: 17700737
    [No Abstract]   [Full Text] [Related]  

  • 17. [Osteoporosis therapy compared. More solid bones with bisphosphonates].
    MMW Fortschr Med; 2003 Aug; 145(31-32):55. PubMed ID: 14524081
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J; Takeda T; Sato Y
    Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A rational approach to evidence gaps in the management of osteoporosis.
    Rosen CJ; Brown SA
    Am J Med; 2005 Nov; 118(11):1183-9. PubMed ID: 16271898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Perspective for development of parathyroid hormone and related compounds as therapeutic agents for osteoporosis].
    Ikeda K; Fukagawa M
    Nihon Rinsho; 2005 Oct; 63 Suppl 10():367-71. PubMed ID: 16279664
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.